Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Aluminum Adjuvant

Phase 3Biologic

XXiamen University

Aluminum Adjuvant is one of 35 biologic programs targeting Papilloma. It is currently in Phase 3.

1

Indications

2

Total Trials

1

Active Trials

34

Competitors

Pipeline

Status by Indication[3][1]

Indication

PapillomaActive, not recruiting

PapillomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Papilloma

#DrugCompanyPhaseTrials

Cervarix

GSK 257049

Comparator: Pbo

Gardasil

Havrix

Engerix-B

Fludara

Libtayo

Opdivo

Bristol-Myers Squibb

Boostrix

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 3Active, not recruiting

Papilloma

NCT06866574

Clinical

Trials by Indication[1]

Immunogenicity1 trial

A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine

Completed·NNational Vaccine and Serum Institute, China·Phase 1·NCT04188691·510 enrolled

Papilloma1 trial

A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males

Active, not recruiting·XXiamen University·Phase 3·NCT06866574·9,300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Aluminum Adjuvant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aluminum Adjuvant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aluminum Adjuvant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiamen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: XXiamen University

Related News